Clinical Trial Update: An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic [Phase 2]

View source ↗

Summary

Phase 2 trial update for continuous 8-hour IV administration of BMS-986231 in heart failure patients on loop diuretics; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• BMS-986231

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cardiac Failure, Myocardial Failure | Phase 2 | Status: COMPLETED | Results posted: 2021-01-26